Source:http://linkedlifedata.com/resource/pubmed/id/20382274
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-5-11
|
| pubmed:abstractText |
Our goal is to compare the immunogenicity and the extent of immunologic reactivity between bispecific and mono anti-idiotype vaccines. We previously obtained two human anti-Id antibody fragments fuse5-G22, fuse5-I50 by phage display technology which were mimics of the antigens from nasopharyngeal carcinoma cell line (HNE2). In this study, we developed and characterized a bispecific anti-Id antibody vaccine G22-I50 and its parent monovalent antibody vaccines G22 and I50. The efficacy of G22-I50, G22, and I50 as tumor vaccines was evaluated in Balb/c mice with three injections of these vaccines adjuvanted with Freund's adjuvant. Mice immunized with G22-I50 exhibited comparable levels of antibody titers and stronger binding inhibition capabilities. Spleen cells from G22-I50-immunized mice gave a significant proliferative response and higher expression level of IFN-gamma and IL-2.These results suggested that bispecific anti-Id antibody vaccine was able to induce more powerful humoral and cell-mediated immune responses, which might make it to be a potential vaccine candidate for the therapy of nasopharyngeal carcinoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bispecific,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Freund's Adjuvant,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1878-1705
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2010 Elsevier B.V. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
707-12
|
| pubmed:meshHeading |
pubmed-meshheading:20382274-Animals,
pubmed-meshheading:20382274-Antibodies, Anti-Idiotypic,
pubmed-meshheading:20382274-Antibodies, Bispecific,
pubmed-meshheading:20382274-Antibodies, Neoplasm,
pubmed-meshheading:20382274-Cancer Vaccines,
pubmed-meshheading:20382274-Carcinoma,
pubmed-meshheading:20382274-Cell Proliferation,
pubmed-meshheading:20382274-Female,
pubmed-meshheading:20382274-Freund's Adjuvant,
pubmed-meshheading:20382274-Humans,
pubmed-meshheading:20382274-Immunity, Cellular,
pubmed-meshheading:20382274-Immunity, Humoral,
pubmed-meshheading:20382274-Interferon-gamma,
pubmed-meshheading:20382274-Interleukin-2,
pubmed-meshheading:20382274-Mice,
pubmed-meshheading:20382274-Mice, Inbred BALB C,
pubmed-meshheading:20382274-Nasopharyngeal Neoplasms,
pubmed-meshheading:20382274-Spleen
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
The ability of human bispecific anti-idiotype antibody to elicit humoral and cellular immune responses in mice.
|
| pubmed:affiliation |
Tumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan, China.
|
| pubmed:publicationType |
Journal Article
|